Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV ‐infected patients in clinical practice: results from a multicentre, observational study

ConclusionsSwitching to dolutegravir + emtricitabine/TDF was associated with similar efficacy and tolerability to switching to elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed patients in clinical practice, although reasons for discontinuation showed differences between regimens. These results should be interpreted with caution, as this is a nonrandomized comparison.

Source: HIV Medicine - November 20, 2018 Category: Infectious Diseases Authors: G Baldin, A Ciccullo, A Capetti, S Rusconi, G Sterrantino, MV Cossu, A Giacomelli, F Lagi, A Latini, P Bagella, A De Luca, S Di Giambenedetto, G Madeddu Tags: Short Communication Source Type: research